Pretreatment and Routine Echocardiogram Monitoring During Chemotherapy for Anthracycline-Induced Cardiotoxicity Rarely Identifies Significant Cardiac Dysfunction or Alters Treatment Decisions: A 5-Year Review at a Single Pediatric Oncology Center
The widespread use of anthracycline chemotherapy has contributed to improved outcomes in children with cancer. The most feared complication of the anthracyclines is cardiotoxicity. Routine echocardiographic monitoring typically is used before, during, and after treatment to minimize cardiotoxicity....
Gespeichert in:
Veröffentlicht in: | Cancer 2012-04, Vol.118 (7), p.1919-1924 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1924 |
---|---|
container_issue | 7 |
container_start_page | 1919 |
container_title | Cancer |
container_volume | 118 |
creator | WATTS, Raymond G GEORGE, Mckenzie JOHNSON, Walter H |
description | The widespread use of anthracycline chemotherapy has contributed to improved outcomes in children with cancer. The most feared complication of the anthracyclines is cardiotoxicity. Routine echocardiographic monitoring typically is used before, during, and after treatment to minimize cardiotoxicity. The ideal use of screening before and during chemotherapy remains uncertain.
This was a retrospective review of children who were treated at a single cancer treatment center over 5 years. The results of all echocardiograms and related clinical decisions were reviewed.
In 356 patients who were identified for review (age range, 3 months to 22 years; mean age, 10 years; median age, 11 years), 991 echocardiograms were reviewed (average, 2.78 echocardiograms per patient; median, 2 echocardiograms per patient; mode, 1; maximum, 11 echocardiograms per patient). Nine abnormal echocardiograms were identified (2.5% of patients and 0.9% of echocardiograms performed). Four echocardiograms were performed during episodes of septic shock, 2 echocardiograms represented false-positive studies after repeat evaluation, and 1 echocardiogram demonstrated mild abnormality of function on the day of surgical resection of a large Wilms tumor. None of the 356 pretreatment echocardiograms altered treatment decisions. In 635 follow-up echocardiograms during treatment, cardiac defects were detected in 2 patients (0.5%).
The routine use of echocardiograms to screen for anthracycline-induced cardiac damage before and during chemotherapy rarely identified significant cardiac damage to impact treatment decisions. Improved screening techniques with better discrimination and predictability are needed. Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment. |
doi_str_mv | 10.1002/cncr.26481 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cncr_26481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21882180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c190t-c7d47ff4cbe7f5d2a63bf355c22dc9c93286d76b9dbf1590f14bf8c1a22c9383</originalsourceid><addsrcrecordid>eNpFkU1vEzEQhlcIREPhwg9Ac-GCtMX2fnOLNgUiFbUKOcAp8o7HidHGjmwH2D_OGSct5WCNrXnm9cy8WfaasyvOmHiPFv2VqMuWP8lmnHVNzngpnmYzxlibV2Xx7SJ7EcKP9GxEVTzPLgRv23TYLPtz5yl6knFPNoK0ClbuGI0luMadQ-mVcVsv9_DFWROdN3YLi-M59Dvau7gjLw8TaOdhbuPOS5xwTPX50qojkoL-rBHdb4MmTrCSnsYJlir9Z7ShAF_N1qYbytTAGZYIiynoo8VonIWT8hjJB1g_NrogNCElwweYQ5V_J-lhRT8N_QKZxkiadjsS3FFSi94g3Fp0o9tO0Kdy8i-zZ1qOgV49xMts_fF63X_Ob24_Lfv5TY68YzHHRpWN1iUO1OhKCVkXgy6qCoVQ2GFXiLZWTT10atC86pjm5aBb5FKIlGyLy-zdvSx6F4InvTl4s5d-2nC2OXm3OXm3OXuX4Df38OE47Ek9ov_MSsDbB0AGlKP20qYt_Oequq54UxR_AUbPqZk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pretreatment and Routine Echocardiogram Monitoring During Chemotherapy for Anthracycline-Induced Cardiotoxicity Rarely Identifies Significant Cardiac Dysfunction or Alters Treatment Decisions: A 5-Year Review at a Single Pediatric Oncology Center</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>WATTS, Raymond G ; GEORGE, Mckenzie ; JOHNSON, Walter H</creator><creatorcontrib>WATTS, Raymond G ; GEORGE, Mckenzie ; JOHNSON, Walter H</creatorcontrib><description>The widespread use of anthracycline chemotherapy has contributed to improved outcomes in children with cancer. The most feared complication of the anthracyclines is cardiotoxicity. Routine echocardiographic monitoring typically is used before, during, and after treatment to minimize cardiotoxicity. The ideal use of screening before and during chemotherapy remains uncertain.
This was a retrospective review of children who were treated at a single cancer treatment center over 5 years. The results of all echocardiograms and related clinical decisions were reviewed.
In 356 patients who were identified for review (age range, 3 months to 22 years; mean age, 10 years; median age, 11 years), 991 echocardiograms were reviewed (average, 2.78 echocardiograms per patient; median, 2 echocardiograms per patient; mode, 1; maximum, 11 echocardiograms per patient). Nine abnormal echocardiograms were identified (2.5% of patients and 0.9% of echocardiograms performed). Four echocardiograms were performed during episodes of septic shock, 2 echocardiograms represented false-positive studies after repeat evaluation, and 1 echocardiogram demonstrated mild abnormality of function on the day of surgical resection of a large Wilms tumor. None of the 356 pretreatment echocardiograms altered treatment decisions. In 635 follow-up echocardiograms during treatment, cardiac defects were detected in 2 patients (0.5%).
The routine use of echocardiograms to screen for anthracycline-induced cardiac damage before and during chemotherapy rarely identified significant cardiac damage to impact treatment decisions. Improved screening techniques with better discrimination and predictability are needed. Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.26481</identifier><identifier>PMID: 21882180</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley-Blackwell</publisher><subject>Adolescent ; Anthracyclines - adverse effects ; Antineoplastic Agents - adverse effects ; Biological and medical sciences ; Cardiology. Vascular system ; Child ; Child, Preschool ; Echocardiography - methods ; Female ; Heart ; Heart Diseases - chemically induced ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Humans ; Infant ; Male ; Medical sciences ; Monitoring, Physiologic ; Retrospective Studies ; Tumors ; Young Adult</subject><ispartof>Cancer, 2012-04, Vol.118 (7), p.1919-1924</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c190t-c7d47ff4cbe7f5d2a63bf355c22dc9c93286d76b9dbf1590f14bf8c1a22c9383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25665173$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21882180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WATTS, Raymond G</creatorcontrib><creatorcontrib>GEORGE, Mckenzie</creatorcontrib><creatorcontrib>JOHNSON, Walter H</creatorcontrib><title>Pretreatment and Routine Echocardiogram Monitoring During Chemotherapy for Anthracycline-Induced Cardiotoxicity Rarely Identifies Significant Cardiac Dysfunction or Alters Treatment Decisions: A 5-Year Review at a Single Pediatric Oncology Center</title><title>Cancer</title><addtitle>Cancer</addtitle><description>The widespread use of anthracycline chemotherapy has contributed to improved outcomes in children with cancer. The most feared complication of the anthracyclines is cardiotoxicity. Routine echocardiographic monitoring typically is used before, during, and after treatment to minimize cardiotoxicity. The ideal use of screening before and during chemotherapy remains uncertain.
This was a retrospective review of children who were treated at a single cancer treatment center over 5 years. The results of all echocardiograms and related clinical decisions were reviewed.
In 356 patients who were identified for review (age range, 3 months to 22 years; mean age, 10 years; median age, 11 years), 991 echocardiograms were reviewed (average, 2.78 echocardiograms per patient; median, 2 echocardiograms per patient; mode, 1; maximum, 11 echocardiograms per patient). Nine abnormal echocardiograms were identified (2.5% of patients and 0.9% of echocardiograms performed). Four echocardiograms were performed during episodes of septic shock, 2 echocardiograms represented false-positive studies after repeat evaluation, and 1 echocardiogram demonstrated mild abnormality of function on the day of surgical resection of a large Wilms tumor. None of the 356 pretreatment echocardiograms altered treatment decisions. In 635 follow-up echocardiograms during treatment, cardiac defects were detected in 2 patients (0.5%).
The routine use of echocardiograms to screen for anthracycline-induced cardiac damage before and during chemotherapy rarely identified significant cardiac damage to impact treatment decisions. Improved screening techniques with better discrimination and predictability are needed. Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment.</description><subject>Adolescent</subject><subject>Anthracyclines - adverse effects</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Echocardiography - methods</subject><subject>Female</subject><subject>Heart</subject><subject>Heart Diseases - chemically induced</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Monitoring, Physiologic</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1vEzEQhlcIREPhwg9Ac-GCtMX2fnOLNgUiFbUKOcAp8o7HidHGjmwH2D_OGSct5WCNrXnm9cy8WfaasyvOmHiPFv2VqMuWP8lmnHVNzngpnmYzxlibV2Xx7SJ7EcKP9GxEVTzPLgRv23TYLPtz5yl6knFPNoK0ClbuGI0luMadQ-mVcVsv9_DFWROdN3YLi-M59Dvau7gjLw8TaOdhbuPOS5xwTPX50qojkoL-rBHdb4MmTrCSnsYJlir9Z7ShAF_N1qYbytTAGZYIiynoo8VonIWT8hjJB1g_NrogNCElwweYQ5V_J-lhRT8N_QKZxkiadjsS3FFSi94g3Fp0o9tO0Kdy8i-zZ1qOgV49xMts_fF63X_Ob24_Lfv5TY68YzHHRpWN1iUO1OhKCVkXgy6qCoVQ2GFXiLZWTT10atC86pjm5aBb5FKIlGyLy-zdvSx6F4InvTl4s5d-2nC2OXm3OXm3OXuX4Df38OE47Ek9ov_MSsDbB0AGlKP20qYt_Oequq54UxR_AUbPqZk</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>WATTS, Raymond G</creator><creator>GEORGE, Mckenzie</creator><creator>JOHNSON, Walter H</creator><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20120401</creationdate><title>Pretreatment and Routine Echocardiogram Monitoring During Chemotherapy for Anthracycline-Induced Cardiotoxicity Rarely Identifies Significant Cardiac Dysfunction or Alters Treatment Decisions: A 5-Year Review at a Single Pediatric Oncology Center</title><author>WATTS, Raymond G ; GEORGE, Mckenzie ; JOHNSON, Walter H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c190t-c7d47ff4cbe7f5d2a63bf355c22dc9c93286d76b9dbf1590f14bf8c1a22c9383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Anthracyclines - adverse effects</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Echocardiography - methods</topic><topic>Female</topic><topic>Heart</topic><topic>Heart Diseases - chemically induced</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Monitoring, Physiologic</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WATTS, Raymond G</creatorcontrib><creatorcontrib>GEORGE, Mckenzie</creatorcontrib><creatorcontrib>JOHNSON, Walter H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WATTS, Raymond G</au><au>GEORGE, Mckenzie</au><au>JOHNSON, Walter H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment and Routine Echocardiogram Monitoring During Chemotherapy for Anthracycline-Induced Cardiotoxicity Rarely Identifies Significant Cardiac Dysfunction or Alters Treatment Decisions: A 5-Year Review at a Single Pediatric Oncology Center</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>118</volume><issue>7</issue><spage>1919</spage><epage>1924</epage><pages>1919-1924</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>The widespread use of anthracycline chemotherapy has contributed to improved outcomes in children with cancer. The most feared complication of the anthracyclines is cardiotoxicity. Routine echocardiographic monitoring typically is used before, during, and after treatment to minimize cardiotoxicity. The ideal use of screening before and during chemotherapy remains uncertain.
This was a retrospective review of children who were treated at a single cancer treatment center over 5 years. The results of all echocardiograms and related clinical decisions were reviewed.
In 356 patients who were identified for review (age range, 3 months to 22 years; mean age, 10 years; median age, 11 years), 991 echocardiograms were reviewed (average, 2.78 echocardiograms per patient; median, 2 echocardiograms per patient; mode, 1; maximum, 11 echocardiograms per patient). Nine abnormal echocardiograms were identified (2.5% of patients and 0.9% of echocardiograms performed). Four echocardiograms were performed during episodes of septic shock, 2 echocardiograms represented false-positive studies after repeat evaluation, and 1 echocardiogram demonstrated mild abnormality of function on the day of surgical resection of a large Wilms tumor. None of the 356 pretreatment echocardiograms altered treatment decisions. In 635 follow-up echocardiograms during treatment, cardiac defects were detected in 2 patients (0.5%).
The routine use of echocardiograms to screen for anthracycline-induced cardiac damage before and during chemotherapy rarely identified significant cardiac damage to impact treatment decisions. Improved screening techniques with better discrimination and predictability are needed. Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment.</abstract><cop>Hoboken, NJ</cop><pub>Wiley-Blackwell</pub><pmid>21882180</pmid><doi>10.1002/cncr.26481</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 2012-04, Vol.118 (7), p.1919-1924 |
issn | 0008-543X 1097-0142 |
language | eng |
recordid | cdi_crossref_primary_10_1002_cncr_26481 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Free Content; Alma/SFX Local Collection |
subjects | Adolescent Anthracyclines - adverse effects Antineoplastic Agents - adverse effects Biological and medical sciences Cardiology. Vascular system Child Child, Preschool Echocardiography - methods Female Heart Heart Diseases - chemically induced Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Infant Male Medical sciences Monitoring, Physiologic Retrospective Studies Tumors Young Adult |
title | Pretreatment and Routine Echocardiogram Monitoring During Chemotherapy for Anthracycline-Induced Cardiotoxicity Rarely Identifies Significant Cardiac Dysfunction or Alters Treatment Decisions: A 5-Year Review at a Single Pediatric Oncology Center |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T13%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20and%20Routine%20Echocardiogram%20Monitoring%20During%20Chemotherapy%20for%20Anthracycline-Induced%20Cardiotoxicity%20Rarely%20Identifies%20Significant%20Cardiac%20Dysfunction%20or%20Alters%20Treatment%20Decisions:%20A%205-Year%20Review%20at%20a%20Single%20Pediatric%20Oncology%20Center&rft.jtitle=Cancer&rft.au=WATTS,%20Raymond%20G&rft.date=2012-04-01&rft.volume=118&rft.issue=7&rft.spage=1919&rft.epage=1924&rft.pages=1919-1924&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.26481&rft_dat=%3Cpubmed_cross%3E21882180%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21882180&rfr_iscdi=true |